Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Addition of Noven Boosts Sales: Hisamitsu
January 17, 2011
- AnGes MG Granted Patent for NFκB Decoy Oligo
January 17, 2011
- Korosho to Accelerate Elimination of Drug-Lag: PS Okamoto
January 17, 2011
- JPA Opposed to Unification of Basic Dispensing Fees
January 17, 2011
- Korosho Considering PAL Amendment in 2012: Mr Masugi
January 17, 2011
- Korosho to Enhance Measures against ifestyle Diseases, Cancer, New-Types of Influenza
January 17, 2011
- Premium for New Drug Development Effective for Solving Drug-Lag Problem: MED Director
January 17, 2011
- Safety Measures for Incretin-Related Drugs Insufficient: Medwatcher Japan
January 17, 2011
- Wholesalers' Services Cost-Effective in Japan: FJPWA Report
January 10, 2011
- FDA Approves Merck's Gardasil for Anal Cancer
January 10, 2011
- Prospects for Simultaneous Global Development: 2
January 10, 2011
- Effective Corporate Tax Rate Down 5%, Max R&D Tax Break Rate Down to 20%
January 10, 2011
- CHMP Issues Positive Opinion for Taiho's TS-1
January 10, 2011
- Hope Is Not a Recruiting Strategy
January 10, 2011
- New Drugs Stimulate Osteoporosis Market: M3 Survey
January 10, 2011
- FDA Requests Additional Analytical Data for Ticagrelor
January 10, 2011
- Nippon Kayaku to Start Clinical Studies for Antibody Biosimilars in 2011
January 10, 2011
- MTPC Licenses Bepotastine to Dong-A of South Korea
January 10, 2011
- Small Pharmacy Operators to Create Their Own Association
January 10, 2011
- Taiyo Not to Reduce No. of Products It Manufactures
January 10, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…